(-0.01%) 5 187.14 points
(0.41%) 39 044 points
(-0.22%) 16 296 points
(0.97%) $79.14
(-0.95%) $2.19
(-0.19%) $2 319.80
(0.11%) $27.57
(-0.26%) $985.80
(0.13%) $0.931
(0.08%) $10.91
(0.11%) $0.800
(0.20%) $91.62
Live Chart Being Loaded With Signals
Glenmark Pharmaceuticals Limited, together with its subsidiaries, develops, manufactures, and markets pharmaceutical products in India, North America, Latin America, Europe, and internationally...
Stats | |
---|---|
本日の出来高 | 213 896 |
平均出来高 | 1.21M |
時価総額 | 288.26B |
EPS | INR-12.45 ( 2024-02-15 ) |
次の収益日 | ( INR7.93 ) 2024-05-15 |
Last Dividend | INR2.50 ( 2023-09-18 ) |
Next Dividend | INR0 ( N/A ) |
P/E | -37.67 |
ATR14 | INR0.775 (0.08%) |
ボリューム 相関
Glenmark Pharmaceuticals 相関
10 最も正の相関 | |
---|---|
AUROPHARMA.NS | 0.938 |
ADORWELD.NS | 0.93 |
ANURAS.NS | 0.923 |
IZMO.NS | 0.914 |
GISOLUTION.NS | 0.907 |
ANMOL.NS | 0.905 |
CAREERP.NS | 0.889 |
KSB.NS | 0.884 |
SETF10GILT.NS | 0.879 |
GTNTEX.NS | 0.876 |
10 最も負の相関 | |
---|---|
KOHINOOR.NS | -0.876 |
SEYAIND.NS | -0.867 |
DEEPINDS.NS | -0.855 |
MERCATOR.NS | -0.849 |
STARTECK.NS | -0.835 |
ALLCARGO.NS | -0.808 |
ORTINLAB.NS | -0.807 |
KBCGLOBAL.NS | -0.803 |
SWANENERGY.NS | -0.803 |
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Glenmark Pharmaceuticals 相関 - 通貨/商品
Glenmark Pharmaceuticals 財務諸表
Annual | 2022 |
収益: | INR127.25B |
総利益: | INR81.88B (64.35 %) |
EPS: | INR10.53 |
FY | 2022 |
収益: | INR127.25B |
総利益: | INR81.88B (64.35 %) |
EPS: | INR10.53 |
FY | 2022 |
収益: | INR121.74B |
総利益: | INR77.14B (63.37 %) |
EPS: | INR33.37 |
FY | 2021 |
収益: | INR108.06B |
総利益: | INR70.62B (65.35 %) |
EPS: | INR34.38 |
Financial Reports:
No articles found.
Glenmark Pharmaceuticals Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
INR2.50 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR2.50 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | INR0.600 | 2002-09-12 |
Last Dividend | INR2.50 | 2023-09-18 |
Next Dividend | INR0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 22 | -- |
Total Paid Out | INR30.90 | -- |
Avg. Dividend % Per Year | 0.37% | -- |
Score | 1.29 | -- |
Div. Sustainability Score | 0.0208 | |
Div.Growth Potential Score | 2.78 | |
Div. Directional Score | 1.402 | -- |
Year | Amount | Yield |
---|---|---|
2002 | INR0 | 0.00% |
2003 | INR0 | 0.00% |
2004 | INR0 | 0.00% |
2005 | INR0 | 0.00% |
2006 | INR0 | 0.00% |
2007 | INR0 | 0.00% |
2008 | INR0 | 0.00% |
2009 | INR0 | 0.00% |
2010 | INR0 | 0.00% |
2011 | INR0 | 0.00% |
2012 | INR0 | 0.00% |
2013 | INR0 | 0.00% |
2014 | INR0 | 0.00% |
2015 | INR0 | 0.00% |
2016 | INR0 | 0.00% |
2017 | INR0 | 0.00% |
2018 | INR2.00 | 0.38% |
2019 | INR2.00 | 0.29% |
2020 | INR2.50 | 0.72% |
2021 | INR2.50 | 0.50% |
2022 | INR2.50 | 0.48% |
2023 | INR2.50 | 0.59% |
2024 | INR0 | 0.00% |
The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
SESHAPAPER.NS | Dividend Knight | 2023-06-07 | Annually | 23 | 1.14% | |
MANAKCOAT.NS | Dividend Junior | 2023-08-22 | Sporadic | 4 | 0.09% | |
GOODYEAR.NS | Dividend Knight | 2023-07-26 | Annually | 5 | 4.02% | |
AVANTIFEED.NS | Dividend Junior | 2023-08-03 | Annually | 14 | 0.86% | |
TRIL.NS | Dividend Junior | 2023-07-27 | Sporadic | 17 | 0.22% | |
PILANIINVS.NS | Dividend Junior | 2023-08-29 | Annually | 13 | 0.56% | |
JKCEMENT.NS | Dividend Junior | 2023-08-01 | Annually | 19 | 0.37% | |
DEVIT.NS | Dividend Junior | 2023-09-22 | Annually | 8 | 0.28% | |
SMSPHARMA.NS | Ex Dividend Junior | 2023-09-22 | Annually | 18 | 0.12% | |
MINDTECK.NS | Dividend Junior | 2023-08-04 | Sporadic | 8 | 0.28% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | -0.0581 | 1.500 | -1.161 | -1.742 | [0 - 0.5] |
returnOnAssetsTTM | 0 | 1.200 | 0 | 0 | [0 - 0.3] |
returnOnEquityTTM | -0.0742 | 1.500 | -1.935 | -2.90 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 0 | 0.800 | -5.00 | -4.00 | [1 - 3] |
quickRatioTTM | 0 | 0.800 | -4.71 | -3.76 | [0.8 - 2.5] |
cashRatioTTM | 0 | 1.500 | -1.111 | -1.667 | [0.2 - 2] |
debtRatioTTM | 0 | -1.500 | 0 | 0 | [0 - 0.6] |
interestCoverageTTM | 1.901 | 1.000 | -0.407 | -0.407 | [3 - 30] |
operatingCashFlowPerShareTTM | 31.65 | 2.00 | 10.00 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 31.65 | 2.00 | 10.00 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0 | -1.500 | 0 | 0 | [0 - 2.5] |
grossProfitMarginTTM | 0.621 | 1.000 | 2.99 | 2.99 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.0740 | 1.000 | -0.520 | -0.520 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0 | 1.000 | -1.111 | -1.111 | [0.2 - 2] |
assetTurnoverTTM | 0 | 0.800 | -3.33 | -2.67 | [0.5 - 2] |
Total Score | 0.0208 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | -40.48 | 1.000 | -4.19 | 0 | [1 - 100] |
returnOnEquityTTM | -0.0742 | 2.50 | -1.244 | -2.90 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 31.65 | 2.00 | 10.00 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 0.245 | 1.500 | 3.88 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 31.65 | 2.00 | 10.00 | 10.00 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | 0.591 | 1.500 | 9.39 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.0729 | 1.000 | -0.678 | 0 | [0.1 - 0.5] |
Total Score | 2.78 |
Glenmark Pharmaceuticals
Glenmark Pharmaceuticals Limited, together with its subsidiaries, develops, manufactures, and markets pharmaceutical products in India, North America, Latin America, Europe, and internationally. The company provides branded and generic formulations in the therapeutic areas of dermatology, respiratory, and oncology; and various active pharmaceutical ingredients. Its product pipeline includes ISB 830 (telazorlimab), an OX40 antagonist monoclonal antibody, which is in Phase 2b clinical trial for the treatment of atopic dermatitis; ISB 1302, a HER2 X CD3 beat bispecific antibody that is in Phase 1/2 clinical trial for the treatment of metastatic HER2-positive breast cancer; and ISB 1342, a CD38 X CD3 beat bispecific antibody, which is in Phase 1 clinical trial for the treatment of relapsed/refractory multiple myeloma. The company's pre-clinical stage product pipeline comprises ISB 880 for the treatment of anti-inflammatory therapy; ISB 1908 and ISB 1909 T-cell engagers for the treatment of oncology; ISB 1442, an innate immune engager for the treatment of oncology; and GRC 39815, an inhibitor of the retinoid-related orphan receptor gamma for the treatment of chronic obstructive pulmonary disorder. It also offers Ryaltris nasal spray for allergic rhinitis. The company was incorporated in 1977 and is based in Mumbai, India.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。